Rapamycin evidence in healthy adults

The strongest case for rapamycin is mechanistic — it inhibits mTOR, the most consistently lifespan-extending intervention in mice across the ITP cohort . Translation to healthy humans is still thin: the PEARL trial (114 adults, 12 months, 5–10 mg weekly) found mild improvements in lean mass and pain but no shift in the inflammatory or metabolic markers it pre-registered. A separate trial of the analog RTB101 showed reduced respiratory infections in older adults, which is the single human signal pointing the same direction as the mouse data.

Among the experts we track, P. Arenwald is the most prominent advocate of low-dose weekly use as 'asymmetric upside,' and K. Levitsky has become more cautious on dose escalation since 2024. The consensus is genuinely mixed — not because the data is contradictory, but because there isn't enough of it.

For most healthy adults under 60 the honest read is: not enough evidence to recommend, not enough harm signal to forbid. The decision turns on how you weigh mechanism vs. RCTs and how comfortable you are using a prescription drug off-label.